Medium-term efficacy of infliximab induction therapy without retreatment in patients with Crohn's disease

Introduction: The high cost of infliximab inhibits the regular retreatment of most of the patients in Hungary with Crohn's disease (CD) after beneficial induction therapy. This study set out to evaluate the medium-term efficacy of induction therapy with infliximab without retreatment in CD patients with chronic activity and/or fistulae refractory to conventional therapy. Methods: A retrospective 1-year review was undertaken of all CD patients with successfully induced remission or fistula closure with 3 infusions of infliximab. Clinical remission was defined as symptom resolution and an estimated Crohn's disease…